ACP
AKTX

Acuta Capital Partners’s Akari Therapeutics AKTX Stock Holding History

Acuta Capital Partners’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-29
Closed -$197K – 54
2016
Q3 		$197K Sell
29
-12
-29% -$93.6K 0.07% 59
2016
Q2 		$446K Buy
41
+18
+78% +$232K 0.21% 52
2016
Q1 		$236K Buy
23
+2
+10% +$20.7K 0.13% 38
2015
Q4 		$247K Buy
+21
New +$312K 0.12% 50

Other funds holding AKTX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Acuta Capital Partners's AKTX Position: Q4 2016 in Review

Acuta Capital Partners sold out of Akari Therapeutics (AKTX) in Q4 2016, closing a stake of 29 shares — an estimated $197K sold.

Acuta Capital Partners first reported a position in AKTX in Q4 2015 and held it in 4 quarters. The position peaked at $446K in Q2 2016. 15 funds tracked by Wall St. Rank hold AKTX as of Q4 2016.

  • Acuta Capital Partners reported no remaining Akari Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Acuta Capital Partners sold 29 Akari Therapeutics shares in Q4 2016, an estimated $197K.
  • Acuta Capital Partners first reported a position in Akari Therapeutics in Q4 2015 and held it in 4 quarters.
  • Acuta Capital Partners's Akari Therapeutics position peaked at $446K in Q2 2016.
  • 15 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2016.

Based on Acuta Capital Partners's 13F filing for Q4 2016, filed 13 Feb 2017.